Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment

Show simple item record

dc.contributor University of Helsinki, Institute of Biotechnology en
dc.contributor.author Wang, Liang
dc.contributor.author Peng, Wen
dc.contributor.author Wu, Tianming
dc.contributor.author Deng, Pengchi
dc.contributor.author Zhao, Ying-Lan
dc.date.accessioned 2019-01-09T09:28:01Z
dc.date.available 2019-01-09T09:28:01Z
dc.date.issued 2018-08-08
dc.identifier.citation Wang , L , Peng , W , Wu , T , Deng , P & Zhao , Y-L 2018 , ' Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment ' , Cell death discovery , vol. 5 , no. 1 . https://doi.org/10.1038/s41420-018-0086-x en
dc.identifier.issn 2058-7716
dc.identifier.other PURE: 115125658
dc.identifier.other PURE UUID: b55a13b6-6b47-4ab3-8564-502d84aeafde
dc.identifier.other RIS: urn:2972393AE90399C20CCC7BD6305AD705
dc.identifier.other RIS: Wang2018
dc.identifier.other WOS: 000463223300001
dc.identifier.uri http://hdl.handle.net/10138/288718
dc.description.abstract To better understand the resistance mechanism of non-small cell lung cancers (NSCLCs) to gefitinib, the metabolic profiles of gefitinib-resistant A549 cells and gefitinib-sensitive PC-9 cells were analyzed with a metabolomics analytical platform. A549 and PC-9 cells exhibited significant differences in the levels of glutamine-related metabolites. After gefitinib treatment, the glutamine level decreased in A549 cells but showed no change in PC-9 cells. The glutamine consumed by A549 cells was used to generate ATP and glutathione (GSH). As glutamine utilization was suppressed in gefitinib-treated PC-9 cells, the resulting ATP shortage and ROS accumulation led to cell death. The difference in glutamine metabolism was caused by differential changes in the levels of glutamine synthetase (GS, encoded by glutamate-ammonia ligase (GLUL)). GLUL expression was upregulated in gefitinib-sensitive cells, but it was either absent from gefitinib-resistant cells or no significant change was observed in the gefitinib-treated cells. GLUL overexpression in A549 cells significant sensitized them to gefitinib and decreased their invasive capacity. Conversely, knockout GS in PC-9 cells reduced gefitinib sensitivity and enhanced metastasis. Furthermore, the continuous exposure of gefitinib-sensitive HCC827 cells to gefitinib created gefitinib-resistant (GR) HCC827 cells, which exhibited a GLUL deletion and resistance to gefitinib. Thus, GLUL plays a vital role in determining the sensitivity of NSCLCs to gefitinib. Elevated GS levels mediate increased glutamine anabolism, and this novel mechanism sensitizes NSCLCs to gefitinib. The inhibition of glutamine utilization may serve as a potential therapeutic strategy to overcome gefitinib resistance in the clinic. en
dc.language.iso eng
dc.relation.ispartof Cell death discovery
dc.rights en
dc.subject 1182 Biochemistry, cell and molecular biology en
dc.title Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1038/s41420-018-0086-x
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
s41420_018_0086_x.pdf 2.587Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record